Related references
Note: Only part of the references are listed.Sativex® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial
Jolana Markova et al.
INTERNATIONAL JOURNAL OF NEUROSCIENCE (2019)
The prevalence of MS in the United States A population-based estimate using health claims data
Mitchell T. Wallin et al.
NEUROLOGY (2019)
Defining the spectrum of spasticity-associated involuntary movements
Hesham Abboud et al.
PARKINSONISM & RELATED DISORDERS (2019)
Assessment and Measurement of Spasticity in MS: State of the Evidence
Cinda L. Hugos et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2019)
Inter- and intra-rater reliability of the Modified Ashworth Scale: a systematic review and meta-analysis
Ana-Belen Meseguer-Henarejos et al.
EUROPEAN JOURNAL OF PHYSICAL AND REHABILITATION MEDICINE (2018)
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
Valery L. Feigin et al.
LANCET NEUROLOGY (2017)
Systematic review of the influence of spasticity on quality of life in adults with chronic neurological conditions
K. Milinis et al.
DISABILITY AND REHABILITATION (2016)
Tetrahydrocannabinol: Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice
Patrick Vermersch et al.
EUROPEAN NEUROLOGY (2016)
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
Susana Otero-Romero et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper
Susana Otero-Romero et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Spasticity in multiple sclerosis: Associations with impairments and overall quality of life
K. Milinis et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
A Cross-Sectional Study of the Impact of Spasticity on Daily Activities in Multiple Sclerosis
Francois Bethoux et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2016)
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis
A. Novotna et al.
EUROPEAN JOURNAL OF NEUROLOGY (2011)
A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis
C. Collin et al.
NEUROLOGICAL RESEARCH (2010)
Validity, reliability, and clinical importance of change in a 0-10 numeric rating scale measure of spasticity: A post hoc analysis of a randomized, double-blind, placebo-controlled trial
John T. Farrar et al.
CLINICAL THERAPEUTICS (2008)
Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis
C. Collin et al.
EUROPEAN JOURNAL OF NEUROLOGY (2007)
Relationship between self-and clinically rated spasticity in spinal cord injury
HE Lechner et al.
ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION (2006)
Spasticity: Clinical perceptions, neurological realities and meaningful measurement
AD Pandyan et al.
DISABILITY AND REHABILITATION (2005)
Prevalence and treatment of spasticity reported by multiple sclerosis patients
MA Rizzo et al.
MULTIPLE SCLEROSIS (2004)